Banner - NPPA Connect

Opinion|Videos|July 4, 2024

A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

Author(s)Alexa Hetzel, MS, PA-C, Andrew Mastro, MS, PA-C , TJ Chao, MPAS, PA-C

The experts discuss combination therapy approaches, safety considerations, and targeted interleukin-17 systemic treatments for plaque psoriasis.

Episodes in this series

4 KOLs are featured on this panel.

EP. 1 Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

4 KOLs are featured on this panel.

EP. 2 Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

4 KOLs are featured on this panel.

EP. 3 Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

4 KOLs are featured on this panel.

EP. 4 A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

4 KOLs are featured on this panel.

EP. 5 Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

4 KOLs are featured on this panel.

EP. 6 Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

4 KOLs are featured on this panel.

EP. 7 TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

4 KOLs are featured on this panel.

EP. 8 Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

4 KOLs are featured on this panel.

EP. 9 Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

4 KOLs are featured on this panel.

EP. 10 Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

4 KOLs are featured on this panel.

EP. 11 Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

4 KOLs are featured on this panel.

EP. 12 Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

4 KOLs are featured on this panel.

EP. 13 When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

4 KOLs are featured on this panel.

EP. 14 Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP. 15 Available Psoriasis, Patient Involvement, and Holistic Treatment

EP. 15 Available Psoriasis, Patient Involvement, and Holistic Treatment

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

1 expert is featured in this series

Addressing Steroid Fear with Non-Steroidal Treatment Options in Psoriasis

ByTina Bhutani-Jacques, MD

September 4th 2026

1 expert is featured in this series

Setting Realistic Treatment Goals for Localized Plaque Psoriasis

ByTina Bhutani-Jacques, MD

September 4th 2026

1 expert is featured in this series

Skin Clearance and PsA Prevention with Biologics in Psoriasis

ByBruce Strober, MD, PhD

September 1st 2026

Don't Be Rash: Recognizing Pediatric Psoriasis and Its Arthritis Risk

ByAndrew C. Krakowski, MD,Lisa Swanson, MD, FAAD,Kaitlyn Bader, Assistant Managing Editor

August 31st 2026

Treating Psoriasis and Alopecia Areata Beyond the Skin: An Integrative Approach

ByPatricia Delgado, DNP, AGPCNP, DCNP, PMHNP,Jennifer Soung, MD,Shannon Heaning, Content Associate

August 29th 2026

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline

Uncovering the Autoimmune Links & Systemic Impact of Chronic Spontaneous Urticaria

10 Skin Cancer Exam Tips

Dermatology Times Conferences & Meetings Calendar: September 2026

Early Recognition and Psychosocial Impact in Male Pattern Hair Loss